CELL AND GENE THERAPY INSIGHTS

July 2021 Issue

Volume 7 Issue 7

Cell and Gene Therapy Insights Volume 7 Issue 7

Featuring

Issue Spotlight: Clinical trial design, supply chain and operations
Other articles
Webinars

SPOTLIGHT

Clinical trial design, supply chain and operations

Editorial

CRISPR gene editing for sickle cell disease: one disease, differentiated approaches

CRISPR gene editing for sickle cell disease: one disease, differentiated approaches

Lisa A Michaels, MD, Bruce E Eaton, PhD
5 August 2021
Read

Innovator Insight

Preparing for pivotal: solving challenges in scale for cell and gene therapy clinical trials

Preparing for pivotal: solving challenges in scale for cell and gene therapy clinical trials

S Viswanathan, R Gaeto, E Goodhue Meyer et al.
6 August 2021
Read

Interview

Strengthening the clinical supply chain for individualized therapies

Strengthening the clinical supply chain for individualized therapies

James Andrew Case
5 August 2021
Read
Driving clinical progress of gene therapy in cystic fibrosis

Driving clinical progress of gene therapy in cystic fibrosis

Uta Griesenbach
28 July 2021
Read
Challenges in the gene therapy of bone marrow failure syndromes

Challenges in the gene therapy of bone marrow failure syndromes

Juan Bueren
16 July 2021
Read
Learning lessons from the long, troubled history of stem cell therapy for future clinical success

Learning lessons from the long, troubled history of stem cell therapy for future clinical success

John EJ Rasko
15 July 2021
Read
Addressing issues in clinical development of AAV-driven gene therapy

Addressing issues in clinical development of AAV-driven gene therapy

Sabah Sallah
14 July 2021
Read

Journal articles

Innovator Insight

When using a closed and automated manufacturing platform, is there an option to maintain flexibility?

When using a closed and automated manufacturing platform, is there an option to maintain flexibility?

Kaman Kim, Carlos Yuraszeck, Joseph O’Connor
12 August 2021
Read

Commentary

Critical need for establishing value that justifies the current rising costs of cell and gene therapy

Critical need for establishing value that justifies the current rising costs of cell and gene therapy

Richard T Maziarz, MD
9 July 2021
Read

Webinars